Related Experiment Videos
Type I growth factor receptors: current status and future work
1ICRF Oncology Unit, Hammersmith Hospital, London, U.K.
Abstract:
The type 1 family of growth factor receptors consists of the epidermal growth factor receptor (EGFR), and ErbB-2, ErbB-3 and ErbB-4. Six ligands are known to bind directly to EGFR, none (at present) to ErbB-2, and a family of ligands collectively called the neuregulins bind to both ErbB-3 and ErbB-4. It is now apparent that the receptors function in various heterodimeric pairs, depending on their concentrations, the concentrations of particular ligands in the environment and some intrinsic degree of dimer selectivity. Overexpression of EGFR, ErbB-2 and ErbB-3 has been found commonly in solid human tumours. ErbB-4 has not yet been examined. The EGFR is also activated by various mutations in brain tumours and possibly in other tumour types. These changes appear to be one of the causes of malignant transformation. They may also provide information regarding the course of disease and response to current treatments. Finally, they are targets for a variety of new forms of treatment being developed in the laboratory, in preclinical models and in a few cases in clinical trials.
Insights
The epidermal growth factor receptor (EGFR) family, including ErbB-2, ErbB-3, and ErbB-4, plays a role in cancer. Mutations and overexpression of these receptors are linked to tumor development and treatment response.
Area of Science:
- Oncology
- Molecular Biology
- Cell Signaling
Background:
- The type 1 family of growth factor receptors comprises EGFR, ErbB-2, ErbB-3, and ErbB-4.
- These receptors interact with various ligands, including EGFR-specific ligands and neuregulins.
- Receptor function is mediated through heterodimeric pairs, influenced by ligand availability and receptor concentrations.
Purpose of the Study:
- To review the role of the type 1 family of growth factor receptors in human cancers.
- To highlight the significance of receptor alterations in tumor development and treatment.
Main Methods:
- Literature review of studies on EGFR family receptors in cancer.
- Analysis of receptor expression, mutation status, and ligand interactions.
Main Results:
- Overexpression of EGFR, ErbB-2, and ErbB-3 is common in solid human tumors.
- EGFR mutations are implicated in brain tumors and potentially other cancer types.
- Altered receptor activity contributes to malignant transformation and influences disease progression.
Conclusions:
- Alterations in EGFR family receptors are crucial in cancer development.
- These receptor changes offer insights into disease prognosis and therapeutic strategies.
- EGFR family members represent promising targets for novel cancer therapies.